Imunexus - IPO for innovative biotechnology company

Wollen Sie auch einen Job wie diesen gewinnen?
Dieser Kunde bekam 240 Logo-Designs von 47 Designern. Dabei wurde dieses Logo-Design Design von logo_s als Gewinner ausgewählt.
Kostenlos anmelden Design Jobs finden- Garantiert
Logo-Design Kurzbeschreibung
We need a logo design for a new biotechnology company based in Melbourne, Australia. The company is called Imunexus, and is preparing for an initial public offering (IPO) on the Australian Stock Exchange (ASX). Imunexus offers a 'plug-and-play' technology platform for rapid development of 'biobetters', the rough equivalent of 'super-generic' drugs. Biobetters are improved biological drugs (e.g. antibodies) that are similar to the original antibody, but have substantive structural modifications that enhance the efficacy of the drug. Biobetters work much better than simple 'biosimilars' which are closer copies of the original drug, and do not work any better than the original drug. Please refer to the attached brief summary, in particular logo design concepts on page 3.
Updates
Project Deadline Extended
Reason: Need to get consensus amongst Board.
Added Tuesday, June 2, 2015
Zielmarkt/( -märkte)
Biotechnology investors - high net worths, sophisticated, and retail
Industrie/Einheitstyp
Biotechnology
Logo Text
Imunexus
Logo Stile, die Sie interessieren können
Pictorial / Combination-Logo
Ein reales Objekt (Text optional)



Figuren-Logo
Logo mit Abbildung oder Zeichen


Sehen und fühlen
Jeder Schieber zeichnet eine der Charakteristiken der Marke des Kunden aus sowie den Stil, den euer Logo widerspiegeln sollte.
Elegant
Fett
Spielerisch
Ernst
Traditionel
Modern
Sympatisch
Professionell
Feminin
Männlich
Bunt
Konservativ
Wirtschaftlich
Gehobenes
Anforderungen
Muss haben
- Please see page 3 of the attached brief. NOTE: We are not committed to the boomerang concept; it is one suggestion. Other concepts are welcome.
Schön zu haben
- Please see page 3 of the attached brief. Innovation, next-generation, breakthrough, combination, nexus.
Sollte nicht haben
- Please see page 3 of the attached brief